Indications
Vinorelbin is indicated:
- In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
- As a single agent, for the treatment of patients with metastatic NSCLC
Pharmacology
Dosage & Administration
Intravenous (Adult):
Cervical cancer: 30 mg/m2 days 1 and 8 of a 21-day treatment cycle.
Breast cancer, Ovarian cancer: 25 mg/m2 dose every 7 days.
Non-small cell lung cancer:
- As single agent: 30 mg/m2 wkly as infusion over 20-30 minutes (after diluting in 125 ml normal saline or glucose 5%) or as slow bolus over 5-10 minutes (after diluting in 20-50 ml normal saline or glucose 5%). Delay subsequent doses if neutrophil count is <2000 cells/mm3 until recovery.
- As combination therapy with cisplatin: 25-30 mg/m2 every 7 days.
Oral (Adult):
Non-small cell lung cancer: 60 mg/m2once wkly for 3 wk, may increase subsequently to 80 mg/m2 once wkly. If neutrophil count is < 500 cells/mm3 or between 500-1000 cells/mm3 on 2 separate occasions, keep dose at 60 mg/m2 for next 3 doses.
Interaction
Contraindications
Side Effects
Pregnancy & Lactation
Precautions & Warnings
Use in Special Populations
Intravenous:
- Cervical cancer: Dose adjustments may be needed.
- Breast cancer, Ovarian cancer: Dose adjustments may be needed.
- Non-small cell lung cancer: Massive liver metastases(>75% of liver volume replaced by the tumour): Decrease dose by 1/3. Bilirubin 2.1-3 mg/100 ml: Reduce IV dose by 50%. Bilirubin >3 mg/100 ml: Reduce IV dose by 75%.
Oral:
- Massive liver metastases(>75% of liver volume replaced by the tumour): Decrease dose by 1/3. Bilirubin 2.1-3 mg/100 ml: Reduce IV dose by 50%. Bilirubin >3 mg/100 ml: Reduce IV dose by 75%.
Reviews
There are no reviews yet.